- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01947634
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
Cross-sectional Study on the Incidence of Sleepiness and Sleep-disordered Breathing in Patients With Fabry Disease
Study Overview
Detailed Description
There are 76 patients with Fabry disease in the region of eastern Switzerland who are observed and treated in the University Hospital Zurich. All patients are encountered in retrospective cohort study, and all patients are asked to participate in the study by obtaining written informed consent.
Eligible Fabry patients are investigated by completion of ESS and one ambulatory overnight respiratory polygraphy (oRP). An ESS over 11 is defined as excessive daytime sleepiness(EDS). An apnoea/hypopnoea index (AHI) over 5 per minute is defined as sleep apnoea. Distinction of obstructive sleep apnoea (OSA) and central sleep apnoea (CSA) is performed by analysis of oRP. Medical history, clinical and laboratory data, and current treatment will be extracted from patient files and the retrospective cohort study, respectively.
The patients are asked to participate in the study at clinically regular follow-up visits. After obtaining informed consent, the subjects are provided for reviewing in- and exclusion criteria. For this, additional laboratory analyses and completion of ESS and patient's health questionnaire (PHQ-9) is required.
The screening visit is encountered in the routine clinical follow-up examination. After obtaining informed consent, the subjects are provided for reviewing in- and exclusion criteria. For this, the laboratory results (s. exclusion criteria), which are part of the routine follow-up examination, are checked, and PHQ-9 and ESS are completed together with the patient.
In case of fulfilling all inclusion criteria without presence of exclusion criteria, the patients are scheduled by telephone call for visit 1 (oRP).
Eligible Fabry patients are investigated one ambulatory overnight respiratory polygraphy (oRP). For this reason, the subjects are asked to pick-up and learn the self-administration of the oRP device (ApneaLink™ Plus (ResMed)). The oRP itself is easily performed at subject's home. The following day, the patients need to return the device, or, alternatively, they can send it by post. After oRP, there is no need for further visits for purpose of the study. The subjects are informed about the results of oRP during the next regular clinical follow-up visit.
ORP is a non-invasive medical examination technique, which is routinely applied to detect sleep-related breathing disorders. For purpose of the oRP, the ApneaLink™ Plus (ResMed), a home sleep testing diagnostic device that provides simple, cost-effective and reliable results, is applied. The subjects will be instructed in the usage of the device, so that they can install themselves in the study night.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
ZH
-
Zurich, ZH, Switzerland, 8091
- University Hospital Zurich, Division of Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria: Established diagnosis of Fabry disease, who
- are 18 years or above
- have signed informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ResMed Apnea Link plus
Overnight respiratory polygraphy is performed in Fabry patients
|
Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence and type of sleep-related breathing disorder in Fabry patients.
Time Frame: Day 1
|
Prevalence and type of sleep-related breathing disorder in Fabry patients measured with overnight ambulatory respiratory polygraphy.
|
Day 1
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Sleep Apnea Syndromes
- Fabry Disease
- Sleepiness
Other Study ID Numbers
- SleepFabry
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom, Germany, Canada
-
Wuerzburg University HospitalTakedaActive, not recruitingLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
China National Center for Cardiovascular DiseasesRecruitingFabry Disease, Cardiac VariantChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
IRCCS Policlinico S. DonatoRecruiting
-
Amicus Therapeutics France SASCompletedFabry Disease | Anderson Fabry DiseaseFrance
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
Clinical Trials on ResMed Apnea Link plus
-
VA Office of Research and DevelopmentCompletedHypertensionUnited States
-
Yonsei UniversityCompleted
-
James A. Haley Veterans Administration HospitalPatient-Centered Outcomes Research Institute; University of South Florida; University... and other collaboratorsCompletedApnea, Sleep | Brain Injury, TraumaticUnited States
-
Janssen Pharmaceutical K.K.Completed
-
Agenus Inc.TerminatedLeukemia, Myeloid, ChronicUnited States, United Kingdom
-
Baylor College of MedicineDuke Cancer InstituteRecruitingMesotheliomaUnited States
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Human Sciences...CompletedTuberculosis | HIV I InfectionSouth Africa
-
Boehringer IngelheimCompleted
-
University of ArizonaJanssen Pharmaceutica N.V., Belgium; Southern Arizona VA Health Care SystemCompletedGastroesophageal Reflux DiseaseUnited States
-
Kaohsiung Veterans General Hospital.UnknownHelicobacter Pylori InfectionTaiwan